Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report)'s share price traded up 6.1% during trading on Friday after the company announced better than expected quarterly earnings. The company traded as high as $35.54 and last traded at $35.22. 316,920 shares were traded during mid-day trading, a decline of 68% from the average session volume of 988,274 shares. The stock had previously closed at $33.21.
The company reported ($0.88) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04.
Analysts Set New Price Targets
CRNX has been the topic of several research analyst reports. Citigroup lifted their price target on shares of Crinetics Pharmaceuticals from $70.00 to $74.00 and gave the stock a "buy" rating in a research note on Thursday, November 14th. Jefferies Financial Group upgraded Crinetics Pharmaceuticals from a "hold" rating to a "buy" rating and set a $55.00 price target for the company in a research note on Wednesday, January 22nd. Wolfe Research started coverage on shares of Crinetics Pharmaceuticals in a research report on Tuesday, February 4th. They issued a "peer perform" rating on the stock. HC Wainwright restated a "buy" rating and issued a $81.00 target price on shares of Crinetics Pharmaceuticals in a research note on Monday, January 13th. Finally, TD Cowen began coverage on shares of Crinetics Pharmaceuticals in a research note on Tuesday, February 11th. They set a "buy" rating on the stock. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $72.64.
View Our Latest Research Report on CRNX
Insider Activity
In other news, insider Dana Pizzuti sold 5,000 shares of Crinetics Pharmaceuticals stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $39.07, for a total transaction of $195,350.00. Following the completion of the transaction, the insider now owns 31,748 shares of the company's stock, valued at $1,240,394.36. The trade was a 13.61 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 6.00% of the company's stock.
Hedge Funds Weigh In On Crinetics Pharmaceuticals
Several hedge funds have recently added to or reduced their stakes in CRNX. Venturi Wealth Management LLC acquired a new stake in shares of Crinetics Pharmaceuticals in the fourth quarter valued at approximately $41,000. State of Wyoming purchased a new stake in Crinetics Pharmaceuticals in the 4th quarter valued at approximately $50,000. Headlands Technologies LLC acquired a new stake in Crinetics Pharmaceuticals during the 4th quarter valued at $52,000. Harvest Fund Management Co. Ltd purchased a new position in Crinetics Pharmaceuticals during the fourth quarter worth $66,000. Finally, Allspring Global Investments Holdings LLC acquired a new position in shares of Crinetics Pharmaceuticals in the third quarter worth $91,000. 98.51% of the stock is currently owned by hedge funds and other institutional investors.
Crinetics Pharmaceuticals Stock Down 0.2 %
The company has a market capitalization of $3.16 billion, a price-to-earnings ratio of -9.13 and a beta of 0.56. The stock has a fifty day moving average price of $40.77 and a two-hundred day moving average price of $49.93.
About Crinetics Pharmaceuticals
(
Get Free Report)
Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.
Further Reading
Before you consider Crinetics Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crinetics Pharmaceuticals wasn't on the list.
While Crinetics Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.